World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
44662
World Ranking
15355
National Ranking
7743

Overview

Robert D. Toto is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research primarily spans the field of Medicine with a strong focus on Endocrinology, Diabetes and Metabolism, Nephrology, and Surgery. Additional areas of study include Cardiology and Cardiovascular Medicine and Molecular Biology.

Their work covers several prominent topics including Diabetes Treatment and Management, Chronic Kidney Disease and Diabetes, Pancreatic function and diabetes, Renal Diseases and Glomerulopathies, Diabetes Management and Research, Acute Kidney Injury Research, and Hormonal Regulation and Hypertension.

Robert D. Toto has contributed to multiple research articles published in well-known scientific venues. Frequent publication venues include:

  • Journal of the American Society of Nephrology
  • Nephrology Dialysis Transplantation
  • Kidney International Reports
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Kidney International

Some recent notable papers authored or co-authored by Robert D. Toto are:

  • An atlas of healthy and injured cell states and niches in the human kidney, 2023, Nature
  • Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial, 2020, The Lancet Diabetes & Endocrinology
  • A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, 2021, Kidney International
  • Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, 2021, The Lancet Diabetes & Endocrinology
  • The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics, 2020, Nephrology Dialysis Transplantation

Robert D. Toto's frequent collaborators include:

  • Peter Rossing
  • Glenn M. Chertow
  • Hiddo J.L. Heerspink
  • John J.V. McMurray
  • David C. Wheeler

Best Publications

  • Dapagliflozin in Patients with Chronic Kidney Disease

    Hiddo J.L. Heerspink;Bergur V. Stefánsson;Ricardo Correa-Rotter;Glenn M. Chertow

  • A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

    Marc A Pfeffer;Emmanuel A. Burdmann;Chao Yin Chen;Mark E. Cooper

  • Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial

    Jackson T. Wright;George Bakris;Tom Greene;Larry Y. Agodoa

  • Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

    Garabed Eknoyan;Gerald J. Beck;Alfred K. Cheung;John T. Daugirdas

  • Preserving renal function in adults with hypertension and diabetes: A consensus approach

    George L. Bakris;Mark Williams;Lance Dworkin;William J. Elliott

  • Sympathetic overactivity in patients with chronic renal failure.

    Richard L. Converse;Tage N. Jacobsen;Robert D. Toto;Charles M T Jost

  • Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis

    Tazeen H. Jafar;Paul C. Stark;Christopher H. Schmid;Marcia Landa

  • Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

    T. H. Jafar;C. H. Schmid;M. Landa;I. Giatras

  • Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

    Pablo E. Pergola;Philip Raskin;Robert D. Toto;Colin J. Meyer

  • Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

    L. Y. Agodoa;L. Appel;G. L. Bakris;G. Beck

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

    Dick de Zeeuw;Tadao Akizawa;Paul Audhya;George L. Bakris

  • Intensive blood-pressure control in hypertensive chronic kidney disease.

    Lawrence J. Appel;Jackson T. Wright;Tom Greene;Lawrence Y. Agodoa

  • Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.

    Alfred K. Cheung;Mark J. Sarnak;Guofen Yan;Michael Berkoben

  • The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

    William F. Keane;Barry M. Brenner;Dick de Zeeuw;Jean-Pierre Grunfeld

  • Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).

    Garabed Eknoyan;Thomas Hostetter;Thomas Hostetter;George L. Bakris;George L. Bakris;Lee Hebert;Lee Hebert

  • Erythropoietic response and outcomes in kidney disease and type 2 diabetes

    Scott D. Solomon;Hajime Uno;Eldrin F. Lewis;Kai Uwe Eckardt

  • Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    David C Wheeler;David C Wheeler;Bergur V Stefánsson;Niels Jongs;Glenn M Chertow

  • Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension.

    Richard L. Converse;Tage N. Jacobsen;Charles M T Jost;Robert D. Toto

  • Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study

    Holly Kramer;Robert D Toto;Ronald M Peshock;Richard Cooper

Frequent Co-Authors

Scott M. Grundy
Scott M. Grundy The University of Texas Southwestern Medical Center
Bernard P. Halloran
Bernard P. Halloran University of California, San Francisco
Jorge H. Capdevila
Jorge H. Capdevila Vanderbilt University
Ronald G. Victor
Ronald G. Victor Cedars-Sinai Medical Center
Paul A. Grayburn
Paul A. Grayburn Baylor University Medical Center
Rajiv Agarwal
Rajiv Agarwal Indiana University – Purdue University Indianapolis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in alternative healthcare career pathways beyond the traditional MD, online degrees offer flexible ways to advance your education in the U.S. Nursing is a popular choice, with online programs for both entry-level and experienced learners. For example, you can explore an online lpn program to quickly enter the nursing field or move forward with an rn to bsn with no clinicals program designed for busy registered nurses. These options help streamline the path to advanced roles with minimal disruption to your current work schedule.

For nurses aiming to reach the highest levels, there are also dnp online programs that can be completed on an accelerated timeline. Those seeking less rigorous pathways may benefit from exploring easy dnp programs that still provide the leadership and clinical skills needed for top-tier positions. These online degrees offer flexible, reputable routes to fulfilling health careers without the extended commitment of a traditional medical degree.

Best Scientists Citing Robert D. Toto

Trending Scientists

Recently Published Articles